Pay in 4 interest-free payments of $7.47 Learn more
Ships within 48 hours · Estimated delivery Aug 22 - Aug 27
These medications can support appetite control and weight loss as part of a provider-guided plan
Trial SOUL (McGuire et al., NEJM 2025) Design Phase 3 / event-driven Population Adults with T2D + ASCVD or CKD Key result Oral semaglutide significantly reduced MACE vs placebo in high-CV-risk T2D
Anti-obesity drug therapy can be offered as an adjunct to a reduced-calorie diet and increased physical activity for weight management in adult patients with an initial body mass index (BMI) of 30 kg/m 2 or 2730 kg/m 2 in the presence of at least one weight-related comorbidity, e.g., dysglycemia, hypertension, dyslipidemia, or obstructive sleep apnea
[16] Wharton S, et al
Ipamorelins pentapeptide structure features non-natural amino acids including aminoisobutyric acid (Aib) and D-2-naphthylalanine (D-2-Nal), contributing to its selective ghrelin receptor binding properties
US$ 27.84
US$ 23.76
US$ 29.24
US$ 24.62
US$ 20.01
